ArticleGene therapy2017
Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis.
Article in Gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Advances in Functional Vascular Stents for Cardiovascular Therapy with Drug Delivery and Computational Design.Pharmaceutics · 2026Review
- Combined sustained and triggered release for sequential viral-transduction from collagen-based scaffolds for tissue regeneration.Biomaterials science · 2025Article
- Recent advances in surface functionalization of cardiovascular stents.Bioactive materials · 2025Review
- Progress towards permanent respiratory support.Current opinion in organ transplantation · 2024Review
- Nanotechnology Innovations in Pediatric Cardiology and Cardiovascular Medicine: A Comprehensive Review.Biomedicines · 2024Review
- Translational Medicine: Towards Gene Therapy of Marfan Syndrome.Journal of clinical medicine · 2022Review
- Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1.Scientific reports · 2022Article
- Stent-Based Gene Delivery for Coronary Disease.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Applying Principles of Regenerative Medicine to Vascular Stent Development.Frontiers in bioengineering and biotechnology · 2022Review
- Adeno-Associated Viral Vector Immobilization and Local Delivery from Bare Metal Surfaces.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Nitrate-functionalized patch confers cardioprotection and improves heart repair after myocardial infarction via local nitric oxide delivery.Nature communications · 2021Article
- The Potential Impact and Timeline of Engineering on Congenital Interventions.Pediatric cardiology · 2020Review
- Nitric Oxide-Producing Cardiovascular Stent Coatings for Prevention of Thrombosis and Restenosis.Frontiers in bioengineering and biotechnology · 2020Review
- Semaphorin-3A protects against neointimal hyperplasia after vascular injury.EBioMedicine · 2019Article
- Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
In-stent restenosis remains an important clinical problem in the era of drug eluting stents. Development of clinical gene therapy protocols for the prevention and treatment of in-stent restenosis is hampered by the lack of adequate local delivery systems. Herein we describe a novel stent-based gene delivery platform capable of providing local arterial gene transfer with adeno-associated viral (AAV) vectors. This system exploits the natural affinity of protein G (PrG) to bind to the Fc region of mammalian IgG, making PrG a universal adaptor for surface immobilization of vector-capturing antibodies (Ab). Our results: 1) demonstrate the feasibility of reversible immobilization of AAV2 vectors using vector tethering by AAV2-specific Ab appended to the stent surface through covalently attached PrG, 2) show sustained release kinetics of PrG/Ab-immobilized AAV2 vector particles into simulated physiological medium in vitro and site-specific transduction of cultured cells, 3) provide evidence of long-term (12 weeks) arterial expression of luciferase with PrG/Ab-tethered AAV2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.